4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

144 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

144 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

424B5 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

S-3MEF - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

424B5 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

S-8 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

10-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

SCHEDULE 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

Raymond James upgraded Dianthus Therapeutics from Outperform to Strong Buy and set a new price target of $123.00

Truist initiated coverage of Dianthus Therapeutics with a rating of Buy and set a new price target of $56.00

William Blair initiated coverage of Dianthus Therapeutics with a rating of Outperform

TD Cowen initiated coverage of Dianthus Therapeutics with a rating of Buy

Oppenheimer initiated coverage of Dianthus Therapeutics with a rating of Outperform and set a new price target of $48.00

Robert W. Baird initiated coverage of Dianthus Therapeutics with a rating of Outperform and set a new price target of $58.00

Cantor Fitzgerald initiated coverage of Dianthus Therapeutics with a rating of Overweight

H.C. Wainwright initiated coverage of Dianthus Therapeutics with a rating of Buy and set a new price target of $40.00

Stifel initiated coverage of Dianthus Therapeutics with a rating of Buy and set a new price target of $44.00

Jefferies initiated coverage of Dianthus Therapeutics with a rating of Buy and set a new price target of $22.00

NEW YORK and WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH) ("Dianthus" or the "Company"), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it closed its previously announced underwritten public offering of 8,470,989 shares of its common stock, including the full exercise by the underwriters of their option to purchase an additional 1,157,407 shares, at a public offering price of $81.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 402,468 shares of its common stock at a pub

NEW YORK and WALTHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH) ("Dianthus" or the "Company"), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the pricing of its previously announced upsized underwritten public offering of 7,313,582 shares of its common stock at a public offering price per share of $81.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 402,468 shares of its common stock at a public offering price of $80.999 per pre-funded warrant. The pre-funded warrants have an exercise price o

NEW YORK and WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH) ("Dianthus" or the "Company"), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it has commenced an underwritten public offering of $400 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Dianthus expects to grant the underwriters a 30-day option to purchase up to an additional $60 million of shares of common stock at the public offering price, l

Early GO decision reached in CAPTIVATE ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A  Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W and 300mg/2mL Q4W in generalized Myasthenia Gravis (gMG) expected to initiate in mid-2026; top-line results anticipated in 2H'28 Phase 2 MoMeNtum trial of claseprubart in Multifocal Motor Neuropathy (MMN) ongoing; top-line results on track for 2H'26 Phase 1 healthy volunteer data for DNTH212 anticipated in 2H'26; update on indication prioritization planned for 1H'26 $514.4 million of cash as of December 31, 2025 provides runway into

Early GO decision reached ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A  Key objectives achieved: Company will maintain the Part A dose of 300mg/2mL S.C. Q2W, plans to engage with regulators to remove the 600mg/4mL S.C. Q2W dose arm from Part B, and expects to enroll up to 256 patients in Part A to randomize 128 patients in Part B Independent DSMB review confirmed GO decision; no related serious infections, no clinical symptoms of autoimmune activation, and no related serious adverse events or discontinuations GO decision supports continued development of claseprubart 300mg/2mL Q2W S.C.

NEW YORK and WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced a conference call and webcast to discuss the interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) scheduled for tomorrow, Monday, March 9, 2026 at 8:00 a.m. ET. Investor Conference Call & Webcast InformationTo access the live conference call by phone, please register here. Conference call participants in the question and ans

NEW YORK and WALTHAM, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on March 2, 2026, to three newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grants consist of non-qualified stock options to purchase an aggregate of 26,000 shares of the Com

NEW YORK and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in the TD Cowen 46th Annual Health Care Conference in Boston. Marino Garcia, CEO of Dianthus Therapeutics, will participate in an analyst-led fireside chat on Tuesday, March 3, 2026 at 1:50 pm EST and will host one-on-one meetings with investors. A webcast of this presentation may be accessed under "News and Events" in the Investors section of the Dianthus Therapeutics website. About Dianthus The

NEW YORK and WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York City. Marino Garcia, CEO of Dianthus Therapeutics, will participate in an analyst-led fireside chat on Thursday, February 12, 2026 at 10:00 am EST and will host one-on-one meetings with investors. A webcast of this presentation may be accessed under "News and Events" in the Investors section of the Dianthus Therapeutics website.

NEW YORK and WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in the 44th Annual J.P. Morgan Healthcare conference in San Francisco. Marino Garcia, CEO of Dianthus Therapeutics, will present a corporate overview on Monday, January 12, 2026 at 3:00 pm PST / 6:00 p.m. EST and will host one-on-one meetings with investors. A webcast of this presentation may be accessed under "News and Events" in the Investors section of the Dianthus Therapeutics website. About

Early GO decision reached in CAPTIVATE ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A  Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W and 300mg/2mL Q4W in generalized Myasthenia Gravis (gMG) expected to initiate in mid-2026; top-line results anticipated in 2H'28 Phase 2 MoMeNtum trial of claseprubart in Multifocal Motor Neuropathy (MMN) ongoing; top-line results on track for 2H'26 Phase 1 healthy volunteer data for DNTH212 anticipated in 2H'26; update on indication prioritization planned for 1H'26 $514.4 million of cash as of December 31, 2025 provides runway into

Early GO decision reached ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A  Key objectives achieved: Company will maintain the Part A dose of 300mg/2mL S.C. Q2W, plans to engage with regulators to remove the 600mg/4mL S.C. Q2W dose arm from Part B, and expects to enroll up to 256 patients in Part A to randomize 128 patients in Part B Independent DSMB review confirmed GO decision; no related serious infections, no clinical symptoms of autoimmune activation, and no related serious adverse events or discontinuations GO decision supports continued development of claseprubart 300mg/2mL Q2W S.C.

NEW YORK and WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced a conference call and webcast to discuss the interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) scheduled for tomorrow, Monday, March 9, 2026 at 8:00 a.m. ET. Investor Conference Call & Webcast InformationTo access the live conference call by phone, please register here. Conference call participants in the question and ans

DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function  Demonstrated superior inhibition of pDCs vs. litifilimab in vitro and superior Ig reductions vs. povetacicept in NHPs highlight the potential for improved clinical benefit in severe autoimmune diseases DNTH212 has the potential to be a first line biologic in multiple autoimmune disorders with patient-friendly S.C. self-administration and Q4W or less frequent dosing IND cleared by FDA in September 2025 and expected to clear in China in Q4'25. Phase 1 study of DNTH212 expected to initiate in

Claseprubart 300mg and 600mg Q2W doses both achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores at Week 13 Claseprubart demonstrated a rapid and sustained onset of action, with both doses achieving statistically significant improvements in MG-ADL and QMG scores at Week 1 Claseprubart 300mg Q2W dose was also statistically significant and clinically meaningful across other key efficacy endpoints, including Minimal Symptom Expression (MSE), Myasthenia Gravis Composite (MGC) Score and the Myasthenia Gravis Quality of Life Scale (MG-QoL-15r) Bot

NEW YORK and WALTHAM, Mass., Sept. 07, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced a conference call and webcast to discuss results from the Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) scheduled for tomorrow, Monday, September 8, 2025 at 8:00 a.m. EDT. Investor Webcast & Conference Call InformationTo access the live conference call by phone, please register here. Conference call participants in the question and answer session should pre-register to receive

Dr. Read brings >30 years of leadership and scientific expertise in the biopharmaceutical industry Previously served as CEO and Founder of Mariana Oncology until its acquisition by Novartis in 2024 and CSO of Ra Pharma until its acquisition by UCB in 2020 NEW YORK and WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Simon Read, Ph.D., to the Company's Board of Directors. Dr. Read is a serial entrepreneur with more than 30 years of biopharmaceutical experi

Mr. King launched the first approved biologic and C5 complement inhibitor into the Myasthenia Gravis market and helped set the foundation for the multi-billion dollar C5 franchise of Alexion Mr. King also led the commercial strategy behind the first FDA-approved, self-administered, subcutaneous biologic for gMG as the Chief Commercial Officer of Ra Pharma, acquired by UCB for $2.5 billion Mr. Kango has >26 years of industry experience spanning senior executive, commercial and business development roles in the pharmaceutical and biotechnology sector NEW YORK and WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology co

Dr. Stavenhagen brings over 20 years of experience in leading drug discovery initiatives, with a focus on monoclonal antibodies targeting neuro diseases Jennifer Davis Ruff also named Vice President, Head of Investor Relations & Corporate Affairs with over 20 years of experience at leading public biopharmaceutical companies NEW YORK and WALTHAM, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer. In this role, Dr.